Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.


Dr. Verma Discusses Biosimilars for Trastuzumab

June 1st 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.

Dr. Denes on the Use of Biosimilars in Oncology

May 30th 2018

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses the use of biosimilars in the treatment of patients with cancer.

Dr. Mitri on Impact of Trastuzumab Biosimilar FDA Approval

May 29th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the impact of the FDA-approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Dr. Ali Explains Misconceptions About Biosimilars

May 25th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

Emerging Trastuzumab Biosimilar May Promote Competition

May 22nd 2018

Elisavet Paplomata, MD, discusses ABP 980 and the impact that biosimilars may have on global access to cancer care.

Dr. Verma Discusses the Approval Process for Biosimilars

May 18th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the FDA approval process for biosimilars.

Dr. Ali on Incorporating Biosimilars into Cancer Treatment

May 15th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the incorporation of biosimilars into cancer treatment.

FDA Approves Epoetin Alfa Biosimilar for Anemia

May 15th 2018

The FDA has approved epoetin alfa-epbx (Retacrit) as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Dr. Verma Discusses Challenges With Biosimilars in Oncology

May 8th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses challenges with integrating biosimilars into practice.

FDA Issues Complete Response Letter for Rituximab Biosimilar

May 3rd 2018

The FDA has issued a complete response letter to Sandoz (Novartis) regarding a biologics license application for the rituximab biosimilar GP2013.

Dr. Slamon Discusses the Future of Biosimilars in Oncology

April 30th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the future of biosimilars in oncology.

Dr. Hurvitz on the FDA Approval Process for Biosimilars

April 30th 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Dr. Callahan on the Potential Benefits of Biosimilars in Breast Cancer

April 28th 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the potential benefit of using biosimilars in the treatment of patients with breast cancer.

Dr. Hurvitz on the Clinical Use of Biosimilars in Oncology

April 27th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.

Lead Author Explains ASCO's Statement on Biosimilars in Oncology

April 26th 2018

Gary H. Lyman, MD, FASCO, discusses ASCO's statement outlining the organization’s commitment to education and guidance regarding the use of biosimilars in the treatment of patients with cancer.

Dr. Slamon on the Use of Trastuzumab and Bevacizumab Biosimilars in Breast Cancer

April 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

Hurvitz Shares Insight on Breaking the Barrier With Biosimilars

April 25th 2018

Sara A. Hurvitz, MD, discusses the development of biosimilars and their potential use in the breast cancer field.

Dr. Slamon Discusses the Approval Process for Biosimilars

April 24th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the approval process for biosimilars.

Dr. Hurvitz on Biosimilars in Breast Cancer

April 23rd 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.

FDA Issues Complete Response Letter for Trastuzumab Biosimilar

April 23rd 2018

Citing the need for additional technical information, the FDA has issued a complete response letter to Pfizer regarding a biologics license application for the trastuzumab (Herceptin) biosimilar PF-05280014.

NEXT PAGE
PREVIOUS PAGE